Trial Outcomes & Findings for Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation (NCT NCT01719367)

NCT ID: NCT01719367

Last Updated: 2019-06-17

Results Overview

After baseline vital signs and ECG are recorded, patients will be asked to perform a baseline standardized (modified Bruce) exercise protocol. Heart rate will be recorded during each stage of the exercise protocol. Patients will be asked to exercise to sub-maximal exertion. After the baseline exercise protocol, patients will be given a single dose of oral atenolol. After a two hour waiting period to allow for peak effect of atenolol, patients will repeat the exercise protocol. The primary study outcome measure will be the difference in pre- and post-atenolol ventricular rate response to exercise. The primary outcome measure will be compared in patients with various polymorphisms in genes that might play a role in the inter-individual response to atenolol.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

38 participants

Primary outcome timeframe

after 5minutes of exercise

Results posted on

2019-06-17

Participant Flow

Participant milestones

Participant milestones
Measure
Atenolol: Ancestral Alleles
Patients will undergo a standardized, graded exercise protocol before and after receiving a dose of oral atenolol. participants have Ancestral Alleles
Atenolol: Variant Carriers
Patients will undergo a standardized, graded exercise protocol before and after receiving a dose of oral atenolol. participants have Variant Carriers
Overall Study
STARTED
19
19
Overall Study
COMPLETED
19
19
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
All Participants
n=38 Participants
all participants
Age, Continuous
70.5 years
n=5 Participants
Sex: Female, Male
Female
4 Participants
n=5 Participants
Sex: Female, Male
Male
34 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=5 Participants
Race (NIH/OMB)
White
38 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
Region of Enrollment
United States
19 participants
n=5 Participants

PRIMARY outcome

Timeframe: after 5minutes of exercise

After baseline vital signs and ECG are recorded, patients will be asked to perform a baseline standardized (modified Bruce) exercise protocol. Heart rate will be recorded during each stage of the exercise protocol. Patients will be asked to exercise to sub-maximal exertion. After the baseline exercise protocol, patients will be given a single dose of oral atenolol. After a two hour waiting period to allow for peak effect of atenolol, patients will repeat the exercise protocol. The primary study outcome measure will be the difference in pre- and post-atenolol ventricular rate response to exercise. The primary outcome measure will be compared in patients with various polymorphisms in genes that might play a role in the inter-individual response to atenolol.

Outcome measures

Outcome measures
Measure
Atenolol: Ancestral Alleles
n=19 Participants
Patients will undergo a standardized, graded exercise protocol before and after receiving a dose of oral atenolol. These patients have Ancestral Alleles
Atenolol: Variant Carriers
n=19 Participants
Patients will undergo a standardized, graded exercise protocol before and after receiving a dose of oral atenolol. These patients have Variant Carriers
Change in Pre- and Post-atenolol Ventricular Rate Response After 5 Minutes of Exercise
-10 beats per minute
Interval -18.6 to -1.4
-13 beats per minute
Interval -20.2 to -5.8

PRIMARY outcome

Timeframe: after 10 amd 15 minutes of exercise

After baseline vital signs and ECG are recorded, patients will be asked to perform a baseline standardized (modified Bruce) exercise protocol. Heart rate will be recorded during each stage of the exercise protocol. Patients will be asked to exercise to sub-maximal exertion. After the baseline exercise protocol, patients will be given a single dose of oral atenolol. After a two hour waiting period to allow for peak effect of atenolol, patients will repeat the exercise protocol. The primary study outcome measure will be the difference in pre- and post-atenolol ventricular rate response to exercise. The primary outcome measure will be compared in patients with various polymorphisms in genes that might play a role in the inter-individual response to atenolol.

Outcome measures

Outcome measures
Measure
Atenolol: Ancestral Alleles
n=19 Participants
Patients will undergo a standardized, graded exercise protocol before and after receiving a dose of oral atenolol. These patients have Ancestral Alleles
Atenolol: Variant Carriers
n=19 Participants
Patients will undergo a standardized, graded exercise protocol before and after receiving a dose of oral atenolol. These patients have Variant Carriers
Change in Pre- and Post-atenolol Ventricular Rate Response After 10 and 15 Minutes of Exercise
After 10 minutes
-11 beats per minute
Interval -21.9 to -0.1
-19.7 beats per minute
Interval -25.6 to -13.9
Change in Pre- and Post-atenolol Ventricular Rate Response After 10 and 15 Minutes of Exercise
After 15 minutes
-25.5 beats per minute
Interval -67.0 to -16.8
-35.2 beats per minute
Interval -53.3 to -17.1

Adverse Events

Atenolol: Ancestral Alleles

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Atenolol: Variant Carriers

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Matthew Kolek, MD

Florida Electrophysiology Associates

Phone: (561) 434-0353

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place